6 Rongve A, Auning E, Ehrt U, et al. Psychosis in Parkinson’s disease. Tidsskr Nor Laegeforen, 2012, 132: 155-158？？
[2]
7 Zammit S, Owen M J, Evans J, et al. Cannabis, COMT and psychotic experiences. Br J Psychiatry, 2011, 199: 380-385？？
[3]
8 Molloy C, Conroy R M, Cotter D R, et al. Is traumatic brain injury a risk factor for schizophrenia? A meta-analysis of case-controlled population-based studies. Schizophr Bull, 2011, 37: 1104-1110？？
[4]
9 David H N, Ansseau M, Abraini J H. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of “intact” animals. Brain Res Brain Res Rev, 2005, 50: 336-360
[5]
10 responses in the rat caudate-putamen and nucleus accumbens of “intact” animals. Brain Res Brain Res Rev, 2005, 50: 336-360
[6]
1 Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med, 2005, 2: e141？？
[7]
2 Awad A G, Voruganti L N. The burden of schizophrenia on caregivers: A review. Pharmacoeconomics, 2008, 26: 149-162？？
[8]
3 Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry, 2007, 64: 1123-1131
[9]
4 Andreasen N C, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry, 1982, 39: 789-794？？
[10]
5 Matsuoka T, Narumoto J, Shibata K, et al. Jealous delusions and dysfunction of the right parietal lobe in early-onset Alzheimer’s disease. J Neuropsychiatry Clin Neurosci, 2011, 23: E29-E30？？
[11]
11 Smith G S, Schloesser R, Brodie J D, et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology, 1998, 18: 18-25？？
[12]
20 Straub R E, Jiang Y, MacLean C J, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet, 2002, 71: 337-348
[13]
21 Nagai T, Kitahara Y, Shiraki A, et al. Dysfunction of dopamine release in the prefrontal cortex of dysbindin deficient sandy mice: An in vivo microdialysis study. Neurosci Lett, 2010, 470: 134-138？？
[14]
24 Park H J, Kim J W, Lee S K, et al. Association between the SLC6A12 gene and negative symptoms of schizophrenia in a Korean population. Psychiatry Res, 2011, 189: 478-479？？
[15]
25 Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet, 2002, 71: 877-892？？
[16]
26 Stefansson H, Sarginson J, Kong A, et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet, 2003, 72: 83-87？？
[17]
29 Lipina T V, Niwa M, Jaaro-Peled H, et al. Enhanced dopamine function in DISC1-L100P mutant mice: Implications for schizophrenia. Genes Brain Behav, 2010, 9: 777-789？？
[18]
34 Mortensen P B, Pedersen C B, Westergaard T, et al. Effects of family history and place and season of birth on the risk of schizophrenia. N Engl J Med, 1999, 340: 603-608？？
[19]
36 van Os J, Pedersen C B, Mortensen P B. Confirmation of synergy between urbanicity and familial liability in the causation of psychosis. Am J Psychiatry, 2004, 161: 2312-2314？？
[20]
40 Tidey J W, Miczek K A. Social defeat stress selectively alters mesocorticolimbic dopamine release: An in vivo microdialysis study. Brain Res, 1996, 721: 140-149？？
[21]
41 Nikulina E M, Arrillaga-Romany I, Miczek K A, et al. Long-lasting alteration in mesocorticolimbic structures after repeated social defeat stress in rats: Time course of mu-opioid receptor mRNA and FosB/DeltaFosB immunoreactivity. Eur J Neurosci, 2008, 27: 2272-2284？？
[22]
43 Brown A S. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull, 2006, 32: 200-202？？
[23]
44 Cannon M, Jones P B, Murray R M. Obstetric complications and schizophrenia: Historical and meta-analytic review. Am J Psychiatry, 2002, 159: 1080-1092？？
[24]
50 Cheer J F, Wassum K M, Heien M L, et al. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci, 2004, 24: 4393-4400？？
[25]
51 Arseneault L, Cannon M, Poulton R, et al. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ, 2002, 325: 1212-1213？？
[26]
52 Arseneault L, Cannon M, Witton J, et al. Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry, 2004, 184: 110-117？？
[27]
53 Henquet C, Murray R, Linszen D, et al. The environment and schizophrenia: The role of cannabis use. Schizophr Bull, 2005, 31: 608-612？？
[28]
55 Chen J, Lipska B K, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet, 2004, 75: 807-821？？
[29]
58 Rosenbaum G, Cohen B D, Luby E D, et al. Comparison of sernyl with other drugs: Simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. AMA Arch Gen Psychiatry, 1959, 1: 651-656
[30]
60 Ban T A, Lohrenz J J, Lehmann H E. Observations on the action of Sernyl-a new psychotropic drug. Can Psychiatr Assoc J, 1961, 6: 150-157
[31]
61 Kegeles L S, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry, 2000, 48: 627-640？？
[32]
64 Castle D J, Murray R M. The neurodevelopmental basis of sex differences in schizophrenia. Psychol Med, 1991, 21: 565-575？？
[33]
67 Swerdlow N R. Are we studying and treating schizophrenia correctly? Schizophr Res, 2011, 130: 1-10
[34]
69 Laruelle M, Abi-Dargham A, van Dyck C H, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA, 1996, 93: 9235-9240？？
[35]
71 Breier A, Su T P, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA, 1997, 94: 2569-2574？？
[36]
72 Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry, 1998, 155: 761-767
[37]
75 Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage, 2006, 29: 409-416？？
[38]
78 Delerue C, Boucart M. The relationship between visual object exploration and action processing in schizophrenia. Cogn Neuropsychiatry, 2012
[39]
80 Seeman P, Corbett R, Van Tol H H. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology, 1997, 16: 93-110; discussion 111-135？？
[40]
81 Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry, 2002, 47: 27-38
[41]
82 Miller G A. Mistreating psychology in the decades of the brain. Perspect Psychol Sci, 2010, 5: 716-743？？
[42]
88 Bindra D. A motivational view of learning, performance, and behavior modification. Psychol Rev, 1974, 81: 199-213？？
[43]
90 Robinson T E, Berridge K C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Brain Res Rev, 1993, 18: 247-291
[44]
91 Angrist B M, Gershon S. The phenomenology of experimentally induced amphetamine psychosis—Preliminary observations. Biol Psychiatry, 1970, 2: 95-107
[45]
92 Angrist B, Rotrosen J, Gershon S. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology (Berl), 1980, 67: 31-38？？
[46]
93 Wise R A. Dopamine, learning and motivation. Nat Rev Neurosci, 2004, 5: 483-494
[47]
94 Shizgal P. Neural basis of utility estimation. Curr Opin Neurobiol, 1997, 7: 198-208？？
[48]
95 Heinz A. Anhedonia—a general nosology surmounting correlate of a dysfunctional dopaminergic reward system? Nervenarzt, 1999, 70: 391-398
[49]
97 Bowers M B Jr. Pathogenesis of acute schizophrenic psychosis. An experimental approach. Arch Gen Psychiatry, 1968, 19: 348-355？？
[50]
98 Coltheart M, Langdon R, McKay R. Delusional belief. Annu Rev Psychol, 2011, 62: 271-298？？
[51]
102 Elkes J, Elkes C. Effect of chlorpromazine on the behavior of chronically overactive psychotic patients. Br Med J, 1954, 2: 560-565？？
[52]
107 Li M, He W, Munro R. Amphetamine selectively enhances avoidance responding to a less salient stimulus in rats. J Neural Transm, 2008, 115: 773-776？？
[53]
109 Li M, He W, Mead A. Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus. Behav Pharmacol, 2009, 20: 84-98？？
[54]
110 Zhang C, Fang Y, Li M. Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: Further evidence. Pharmacol Biochem Behav, 2011, 98: 155-160？？
[55]
112 Olney J W, Farber N B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry, 1995, 52: 998-1007？？
[56]
12 Vollenweider F X, Vontobel P, Oye I, et al. Effects of (S)-ketamine on striatal dopamine: A [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res, 2000, 34: 35-43？？
[57]
13 Di Forti M, Lappin J M, Murray R M. Risk factors for schizophrenia—All roads lead to dopamine. Eur Neuropsychopharmacol, 2007, 17 Suppl 2: S101-107？？
[58]
14 Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry, 2003, 160: 13-23？？
[59]
15 Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27: 1081-1090？？
[60]
16 Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis—Linking biology, pharmacology and phenomenology of psychosis. Schizophr Res, 2005, 79: 59-68？？
[61]
17 Kapur S. How antipsychotics become anti-“psychotic”—From dopamine to salience to psychosis. Trends Pharmacol Sci, 2004, 25: 402-406？？
[62]
18 Howes O D, Kapur S. The dopamine hypothesis of schizophrenia: Version III—The final common pathway. Schizophr Bull, 2009, 35: 549-562？？
[63]
19 Richards M, Iijima Y, Kondo H, et al. Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population. Behav Brain Funct, 2006, 2: 39？？
[64]
22 Shao L, Shuai Y, Wang J, et al. Schizophrenia susceptibility gene dysbindin regulates glutamatergic and dopaminergic functions via distinctive mechanisms in Drosophila. Proc Natl Acad Sci USA, 2011, 108: 18831-18836？？
[65]
23 Sun Y, Zhang J, Yuan Y, et al. Study of a possible role of the monoamine oxidase A (MAOA) gene in paranoid schizophrenia among a Chinese population. Am J Med Genet B Neuropsychiatr Genet, 2012, 159B: 104-111
[66]
27 Hennah W, Thomson P, Peltonen L, et al. Genes and schizophrenia: Beyond schizophrenia: The role of DISC1 in major mental illness. Schizophr Bull, 2006, 32: 409-416
[67]
28 Blackwood D H, Visscher P M, Muir W J. Genetic studies of bipolar affective disorder in large families. Br J Psychiatry, 2001, 178: S134-136？？
[68]
30 Niwa M, Kamiya A, Murai R, et al. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron, 2010, 65: 480-489？？
[69]
31 Harrison P J, Owen M J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet, 2003, 361: 417-419？？
[70]
32 Cardno A G, Rijsdijk F V, Sham P C, et al. A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry, 2002, 159: 539-545？？
[71]
33 Mittal V A, Ellman L M, Cannon T D. Gene-environment interaction and covariation in schizophrenia: The role of obstetric complications. Schizophr Bull, 2008, 34: 1083-1094？？
[72]
35 Pedersen C B, Mortensen P B. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch Gen Psychiatry, 2001, 58: 1039-1046？？
[73]
37 Cantor-Graae E, Selten J P. Schizophrenia and migration: A meta-analysis and review. Am J Psychiatry, 2005, 162: 12-24？？
[74]
38 Janssen I, Hanssen M, Bak M, et al. Discrimination and delusional ideation. Br J Psychiatry, 2003, 182: 71-76？？
[75]
39 Hall F S, Wilkinson L S, Humby T, et al. Isolation rearing in rats: Pre- and postsynaptic changes in striatal dopaminergic systems. Pharmacol Biochem Behav, 1998, 59: 859-872？？
[76]
42 Anstrom K K, Miczek K A, Budygin E A. Increased phasic dopamine signaling in the mesolimbic pathway during social defeat in rats. Neuroscience, 2009, 161: 3-12？？
[77]
45 Brown A S, Susser E S. Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophr Bull, 2008, 34: 1054-1063？？
[78]
46 Hall F S, Wilkinson L S, Humby T, et al. Maternal deprivation of neonatal rats produces enduring changes in dopamine function. Synapse, 1999, 32: 37-43？？
[79]
47 Boksa P, El-Khodor B F. Birth insult interacts with stress at adulthood to alter dopaminergic function in animal models: Possible implications for schizophrenia and other disorders. Neurosci Biobehav Rev, 2003, 27: 91-101？？
[80]
48 Pruessner J C, Champagne F, Meaney M J, et al. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: A positron emission tomography study using [11C]raclopride. J Neurosci, 2004, 24: 2825-2831？？
[81]
49 Boileau I, Dagher A, Leyton M, et al. Modeling sensitization to stimulants in humans: An [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry, 2006, 63: 1386-1395？？
[82]
54 Tunbridge E M, Harrison P J, Weinberger D R. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry, 2006, 60: 141-151
[83]
56 Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology, 2006, 31: 2748-2757？？
[84]
57 Caspi A, Moffitt T E, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol Psychiatry, 2005, 57: 1117-1127？？
[85]
59 Luby E D, Cohen B D, Rosenbaum G, et al. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry, 1959, 81: 363-369？？
[86]
62 Cubells J F, Feinn R, Pearson D, et al. Rating the severity and character of transient cocaine-induced delusions and hallucinations with a new instrument, the Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis (SAPS-CIP). Drug Alcohol Depend, 2005, 80: 23-33？？
[87]
63 McGrath J J. Variations in the incidence of schizophrenia: Data versus dogma. Schizophr Bull, 2006, 32: 195-197
[88]
65 Munro C A, McCaul M E, Wong D F, et al. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry, 2006, 59: 966-974？？
[89]
66 Smith R C, Calderon M, Ravichandran G K, et al. Nuclear magnetic resonance in schizophrenia: A preliminary study. Psychiatry Res, 1984, 12: 137-147？？
[90]
68 Meyer-Lindenberg A, Miletich R S, Kohn P D, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci, 2002, 5: 267-271？？
[91]
70 Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. J Psychopharmacol, 1999, 13: 358-371？？
[92]
73 Huttunen J, Heinimaa M, Svirskis T, et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry, 2008, 63: 114-117？？
[93]
74 Brunelin J, d’Amato T, van Os J, et al. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr Res, 2008, 100: 206-211？？
[94]
76 Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist, 2003, 9: 404-416？？
[95]
77 Andreasen N C. A unitary model of schizophrenia: Bleuler’s “fragmented phrene” as schizencephaly. Arch Gen Psychiatry, 1999, 56: 781-787？？
[96]
79 Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry, 2001, 158: 360-369？？
[97]
83 Wise R A, Spindler J, deWit H, et al. Neuroleptic-induced “anhedonia” in rats: Pimozide blocks reward quality of food. Science, 1978, 201: 262-264？？
[98]
84 Schultz W. Getting formal with dopamine and reward. Neuron, 2002, 36: 241-263？？
[99]
85 Phillips P E, Stuber G D, Heien M L, et al. Subsecond dopamine release promotes cocaine seeking. Nature, 2003, 422: 614-618？？
[100]
86 Berridge K C, Robinson T E. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev, 1998, 28: 309-369
[101]
87 Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol, 1998, 12: 54-67？？
[102]
89 Toates F. The interaction of cognitive and stimulus-response processes in the control of behaviour. Neurosci Biobehav Rev, 1998, 22: 59-83
[103]
96 Bowers M B Jr, Freedman D X. “Psychedelic” experiences in acute psychoses. Arch Gen Psychiatry, 1966, 15: 240-248？？
[104]
99 Miller R. The time course of neuroleptic therapy for psychosis: Role of learning processes and implications for concepts of psychotic illness. Psychopharmacology (Berl), 1987, 92: 405-415
[105]
100 Clody D E, Carlton P L. Stimulus efficacy, chlorpromazine, and schizophrenia. Psychopharmacology (Berl), 1980, 69: 127-131？？
[106]
101 Mizrahi R, Bagby R M, Zipursky R B, et al. How antipsychotics work: The patients’ perspective. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29: 859-864？？
[107]
103 Phillips P, Johnson S. How does drug and alcohol misuse develop among people with psychotic illness? A literature review. Soc Psychiatry Psychiatr Epidemiol, 2001, 36: 269-276？？
[108]
104 Courvoisier S. Pharmacodynamic properties of chlorpromazine in relation to its use in psychiatry. Encephale, 1956, 45: 1248-1257
[109]
105 Johnson F N. Stimulus significance and chlorpromazine effects on the expression of avoidance learning in mice. Neuropharmacology, 1971, 10: 267-272？？
[110]
106 Li M, Parkes J, Fletcher P J, et al. Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacol Biochem Behav, 2004, 78: 811-819？？
[111]
108 Li M, Fletcher P J, Kapur S. Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology, 2007, 32: 263-272？？
[112]
111 Lewis D A, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci, 2002, 25: 409-432？？
